Slowing arterial aging: How far have we progressed?

Journal of Hypertension

Volumn 25, Issue 3, 2007, Pages 509-510

  Scuteri, Angelo ^a  

^a INRCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALAGEBRIUM; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGING; ARTERY AGING; ARTERY BLOOD FLOW; ARTERY DIAMETER; BLOOD PRESSURE; BLOOD VESSEL CAPACITANCE; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; EDITORIAL; HEART OUTPUT; HUMAN; NONHUMAN; PRIORITY JOURNAL; PULSE WAVE; SYSTOLIC HYPERTENSION; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 33846840793     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328017f71c     Document Type: Editorial

References (15)

1. Najjar SS, Scuteri A, Lakatta EG. Arterial aging: is it an immutable cardiovascular risk factor? Hypertension 2005; 46:454-462.
2. Zieman SJ, Melenovsky V, Clattenburg L, Corretti MC, Capriotti A, Gerstenblith G, Kass DA. Advanced glycation endproduct cross-link breaker (alagebrium) improves endothelial dysfunction in patients with isolated systolic hypertension. J Hypertens 2007; 25:577-583.
3. Nichols WW, O'Rourke MF. McDonald's blood flow in arteries: theoretical, experimental and clinical principles, 5th ed. London: Hodder Arnold; 2005.
4. Scuteri A, Chen CH, Yin FC, Chih-Tai T, Spurgeon HA, Lakatta EG. Functional correlates of central arterial geometric phenotypes. Hypertension 2001; 38:1471-1475.
5. Scuteri A, Manolio TA, Marino EK, Arnold AM, Lakatta EG. Prevalence of specific variant carotid geometric patterns and incidence of cardiovascular events in older persons. The Cardiovascular Health Study (CHS E-131). J Am Coll Cardiol 2004; 43:187-193.
6. Liao D, Arnett DK, Tyroler HA, Riley WA, Chambless LE, Szklo M, Heiss G. Arterial stiffness and the development of hypertension. The ARIC study. Hypertension 1999; 34:201-206.
7. Dernellis J, Panaretou M. Aortic stiffness is an independent predictor of progression to hypertension in nonhypertensive subjects. Hypertension 2005; 45:426-431.
8. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104:1464-7140.
9. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11:191-195.
10. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004; 53:1813-1823.
11. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, et al. Prevention of accelerated atherosclerosis by angiotensin- converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002; 106:246-253.
12. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002; 13:2478-2487.
13. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51:3274-3282.
14. Coughlan MT, Thallas-Bonke V, Pete J, Long DM, Gasser A, Tong DC, et al. Combination therapy with the AGE cross-link breaker, alagebrium and angiotensin converting enzyme inhibitors in diabetes: Synergy or redundancy? Endocrinology 2006; Nov 16 [Epub ahead of print].
15. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al., for the European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27:2588-2605.